But relying on Omicron-specific vaccines is risky, experts say, because there's no guarantee they'll work against the next variant, or even provide strong protection against other existing variants.
"Although with the mRNA, that's a spectacular success story, I don't think we should rest on our laurels, and we should look at how do we get a platform and... design that might give a broader and more durable protection," Fauci added.It's impossible to predict what the next problematic variant will be. That likely requires investment in multiple vaccine candidates and technologies, including ones that target different variants or different parts of the virus.
Some experts say we also need new vaccines that are delivered differently, such as orally or via absorption through the skin, and that don't require cold-chain storage. These could help immensely with global vaccination. Regardless, it's important to have multiple antivirals. Although they generally work well against different variants, the virus can mutate to become resistant to them.
$IBRX ... check it out...
OWS 2.0 is administration recognising Trump contribution to fighting against covid. NVAX meets most requirements cross immugencity and regular cold chain
narsoplimab is currently only therapeutic still in ispy trial.
Less greed on the part of big pharma might help, too.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Carscoop - 🏆 306. / 63 Read more »
Source: Carscoop - 🏆 306. / 63 Read more »
Source: WSJ - 🏆 98. / 63 Read more »
Source: sciam - 🏆 300. / 63 Read more »
Source: CBSLA - 🏆 552. / 51 Read more »
Source: MarketWatch - 🏆 3. / 97 Read more »